Absence of association between polymorphisms in the pfcoronin and pfk13 genes and the presence of Plasmodium falciparum parasites after treatment with artemisinin derivatives in Senegal

• Published in: International journal of antimicrobial agents Vol. 56; no. 6; p. 106190
• Main Authors: Delandre, Océane, Daffe, Sokhna M., Gendrot, Mathieu, Diallo, Maguette N., Madamet, Marylin, Kounta, Mame B., Diop, Moustapha N., Bercion, Raymond, Sow, Abdou, Ngom, Papa M., Lo, Gora, Benoit, Nicolas, Amalvict, Rémy, Fonta, Isabelle, Mosnier, Joel, Diawara, Silman, Wade, Khalifa A., Fall, Mansour, Fall, Khadidiatou B., Fall, Bécaye, Pradines, Bruno
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.12.2020; Elsevier
• Subjects: Artemisinin; Coronin; Life Sciences; Microbiology and Parasitology; Molecular marker; Parasitology; pfk13; Plasmodium falciparum; Resistance; Resistance; Plasmodium falciparum; Molecular marker; Coronin; pfk13; Artemisinin
• ISSN: 0924-8579; 1872-7913
• DOI: 10.1016/j.ijantimicag.2020.106190

•348 P. falciparum samples from 327 patients collected from 2015–2019 in Hôpital Principal de Dakar, Senegal.•16 patients (4.9%) still parasitaemic on Day 3 after t artemisinin-based combination therapy (ACT).•All sequences had wild-type pfk13 allele.•Identification of P76S mutation in pfcoronin (mean prevalence16.2%).•No significant association between in vivo reduced efficacy to ACT and P76S mutation. Due to resistance to chloroquine and sulfadoxine/pyrimethamine, treatment for uncomplicated Plasmodium falciparum malaria switched to artemisinin-based combination therapy (ACT) in 2006 in Senegal. Several mutations in the gene encoding the kelch13 helix (pfk13-propeller) have been identified as associated with in vitro and in vivo artemisinin resistance in Southeast Asia. Additionally, three mutations in the pfcoronin gene (G50E, R100K and E107V) have been identified in two culture-adapted Senegalese field isolates that became resistant in vitro to artemisinin after 4 years of intermittent selection with dihydroartemisinin. The aims of this study were to assess the prevalence of pfcoronin and pfk13 mutations in Senegalese field isolates from Dakar and to investigate their association with artemisinin derivative clinical failures. A total of 348 samples of P. falciparum from 327 patients, collected from 2015–2019 in Dakar, were successfully analysed. All sequences had wild-type pfk13 allele. The three mutations (G50E, R100K and E107V), previously identified in parasites with reduced susceptibility to artemisinin, were not found in this study, but a new mutation (P76S) was detected (mean prevalence 16.2%). The P76S mutation was identified in 5 (31.3%) of 16 isolates collected from patients still parasitaemic on Day 3 after ACT treatment and in 31 samples (15.3%) among 203 patients considered successfully cured. There was no significant association between in vivo reduced efficacy to artemisinin derivatives and the P76S mutation (P = 0.151, Fisher's exact test). These data suggest that polymorphisms in pfk13 and pfcoronin are not the best predictive markers for artemisinin resistance in Senegal.